Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer.
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Trillium Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TRIL's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: TRIL exceeded the Canadian Biotechs industry which returned 29.6% over the past year.
Return vs Market: TRIL exceeded the Canadian Market which returned -11% over the past year.
Price Volatility Vs. Market
How volatile is Trillium Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWhat Kind Of Shareholder Owns Most Trillium Therapeutics Inc. (TSE:TRIL) Stock?
3 months ago | Simply Wall StIntroducing Trillium Therapeutics (TSE:TRIL), The Stock That Zoomed 211% In The Last Year
1 year ago | Simply Wall StThe Trillium Therapeutics (TSE:TRIL) Share Price Is Down 95% So Some Shareholders Are Rather Upset
Is Trillium Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TRIL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TRIL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TRIL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: TRIL is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TRIL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TRIL is overvalued based on its PB Ratio (7.8x) compared to the CA Biotechs industry average (5x).
How is Trillium Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TRIL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TRIL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TRIL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TRIL is forecast to have no revenue next year.
High Growth Revenue: TRIL is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TRIL's Return on Equity is forecast to be high in 3 years time
How has Trillium Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TRIL is currently unprofitable.
Growing Profit Margin: TRIL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TRIL is unprofitable, and losses have increased over the past 5 years at a rate of -30.9% per year.
Accelerating Growth: Unable to compare TRIL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRIL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: TRIL has a negative Return on Equity (-123.24%), as it is currently unprofitable.
How is Trillium Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: TRIL's short term assets ($138.0M) exceed its short term liabilities ($22.8M).
Long Term Liabilities: TRIL's short term assets ($138.0M) exceed its long term liabilities ($33.0M).
Debt to Equity History and Analysis
Debt Level: TRIL is debt free.
Reducing Debt: TRIL has no debt compared to 5 years ago when its debt to equity ratio was 1%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TRIL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: TRIL has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 23.4% each year
What is Trillium Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TRIL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TRIL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TRIL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TRIL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TRIL's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Jan Skvarka, Ph.D., is the President, Chief Executive Officer and Director of Trillium Therapeutics Inc. since September 25, 2019. Before joining Trillium, he was the Chief Executive Officer and Presid ...
|Executive Chairman||1.08yrs||US$177.78k||no data|
|Chief Financial Officer||8.75yrs||US$766.47k||no data|
|Chief Scientific Officer||7.08yrs||US$841.24k||no data|
|Chief Development Officer||5yrs||US$766.47k||no data|
|Chief Medical Officer||2.08yrs||US$2.01m||no data|
|President||0.67yr||no data||no data|
|Head of Calgary Site||no data||no data||no data|
|Senior Vice President - Clinical Operations||1.33yrs||no data||no data|
Experienced Management: TRIL's management team is considered experienced (3.5 years average tenure).
|Executive Chairman||1.08yrs||US$177.78k||no data|
|President||0.67yr||no data||no data|
|Independent Director||7.08yrs||US$174.45k||no data|
|Independent Director||0.25yr||no data||no data|
|Independent Director||6.17yrs||US$180.45k||no data|
|Independent Director||8.83yrs||US$204.45k||0.011% $78.3k|
|Independent Director||6.17yrs||US$179.45k||no data|
|Independent Director||2.58yrs||US$176.37k||no data|
|Member of Scientific and Clinical Advisory Board||8.42yrs||no data||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
Experienced Board: TRIL's board of directors are considered experienced (6.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 217.4%.
Trillium Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Trillium Therapeutics Inc.
- Ticker: TRIL
- Exchange: TSX
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$700.032m
- Shares outstanding: 83.44m
- Website: https://www.trilliumtherapeutics.com
Number of Employees
- Trillium Therapeutics Inc.
- 2488 Dunwin Drive
- L5L 1J9
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TRIL||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Jan 2005|
|R5WP||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jan 2005|
|TRIL||NasdaqCM (Nasdaq Capital Market)||Yes||Common Shares||US||USD||Jan 2005|
|0VLS||LSE (London Stock Exchange)||Yes||Common Shares||GB||CAD||Jan 2005|
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase Ib clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and TTI-2341, an epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/29 03:15|
|End of Day Share Price||2020/05/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.